• PD0325901: Selective MEK Inhibitor for Pathway & Cancer Rese

  2026-05-18

  PD0325901 is a potent and selective MEK inhibitor validated in both in vitro and in vivo models of RAS/RAF/MEK/ERK signaling pathway inhibition. It induces cell cycle arrest and apoptosis in cancer cells and robustly suppresses tumor growth in xenograft models. Product performance and mechanism are supported by peer-reviewed literature and validated product specifications.

• Propranolol: Metabolic Pathways and Advanced Research Protoc

  2026-05-17

  Explore Propranolol as a non-selective β-adrenergic receptor blocker with a focus on its unique metabolic pathway modulation and evidence-based research protocols. This article offers a deeper mechanistic perspective, informed by cutting-edge clinical data and practical assay guidance.

• Lenalidomide (CC-5013): Optimizing Immune Activation in Myel

  2026-05-16

  Lenalidomide (CC-5013) stands at the forefront of immune system activation and epigenetic synergy for multiple myeloma research. This article translates the latest mechanistic breakthroughs—such as DOT1L inhibition—into actionable protocols, troubleshooting strategies, and workflow enhancements for translational and preclinical scientists.

• EZ Cap EGFP mRNA 5-moUTP: Stability and Expression Benchmark

  2026-05-15

  EZ Cap EGFP mRNA 5-moUTP enables robust, immune-evasive expression of enhanced green fluorescent protein in vitro and in vivo. Its Cap 1 structure and 5-methoxyuridine modifications enhance translation efficiency, stability, and reduce innate immune activation.

• Optimizing iNOS & NF-κB Assays with PPM-18 (SKU C4074): Evid

  2026-05-15

  This article addresses key laboratory challenges in cell viability, proliferation, and inflammation assays, demonstrating how PPM-18 (N-(1,4-dihydro-1,4-dioxo-2-naphthalenyl)-benzamide, SKU C4074) delivers data-backed solutions. Scenario-driven Q&A blocks guide biomedical researchers through experimental optimization, result interpretation, and reliable product sourcing for robust NF-κB and iNOS pathway studies.

• RNAi Screen Identifies Vesicular Transport in SARS-CoV-2 Rel

  2026-05-14

  Kerr et al. conducted an arrayed RNA interference screen in human cells to systematically identify host factors supporting SARS-CoV-2 replication, focusing on the underexplored stages of viral assembly and release. Their work reveals a critical role for vesicle-mediated exocytic transport—especially Rab11a-mediated cargo delivery—and demonstrates that pharmacological inhibition of CDK9 disrupts viral egress, providing a foundation for host-targeted antiviral strategies.

• ORM2 Modulates Autophagy and Pancreatic Fibrosis via ZG16

  2026-05-14

  This study identifies ORM2 as a critical regulator of pancreatic fibrosis in chronic pancreatitis, acting through inhibition of autophagy in pancreatic stellate cells via ZG16 binding. These findings elucidate a novel anti-fibrotic mechanism and suggest ORM2 as a potential therapeutic target for pancreatic fibrotic disease.

• (Z)-4-Hydroxytamoxifen: Mechanistic Precision in Estrogen Mo

  2026-05-13

  (Z)-4-Hydroxytamoxifen is a potent estrogen receptor modulator enabling mechanistic clarity and experimental reproducibility in breast cancer and endocrine signaling studies. Explore its unique binding properties, protocol optimization, and nuanced assay roles beyond conventional applications.

• Multiplexed mRNA and Protein Detection in Avian Hair Cell Re

  2026-05-13

  Sato et al. present a protocol enabling in vivo elimination of avian auditory hair cells, followed by simultaneous multiplexed mRNA detection, immunohistochemistry, and S-phase labeling. This integrated workflow offers high-resolution insight into gene and protein dynamics during sensory hair cell loss and regeneration, providing a robust platform for regenerative biology research.

• HyperScript III RT SuperMix: Precision cDNA Synthesis for qP

  2026-05-12

  HyperScript III RT SuperMix enables high-fidelity, contamination-free cDNA synthesis, optimizing gene expression analysis by qPCR. Its engineered reverse transcriptase demonstrates superior performance with low-concentration and high-GC content RNA. Integrated gDNA removal ensures accurate results for sensitive applications.

• Monomethyl Auristatin E (MMAE): Payload Precision in ADC Des

  2026-05-12

  Explore the unique precision of Monomethyl auristatin E (MMAE) as an antibody-drug conjugate payload for advanced cancer therapy. This article offers fresh scientific insight into MMAE’s mechanism, assay optimization, and the impact of epigenetic plasticity on its deployment.

• I-BET151 (GSK1210151A): Technical Guidance for BET Inhibitio

  2026-05-11

  I-BET151 (GSK1210151A) is a selective BET bromodomain inhibitor designed for precise modulation of gene expression in cancer research workflows. It is optimized for apoptosis and cell cycle arrest assays, particularly in MLL-fusion leukemia models. This product is intended strictly for scientific research and should not be used for diagnostic or medical purposes.

• Doxycycline: Optimizing Tetracycline Antibiotic Workflows in

  2026-05-11

  Doxycycline stands out beyond its role as a tetracycline antibiotic, offering potent metalloproteinase inhibition and antiproliferative effects for advanced cancer and matrix biology research. Explore data-driven protocols and troubleshooting strategies that maximize reproducibility and impact, with a spotlight on APExBIO’s rigorously validated BA1003 formulation.

• (S)-(+)-Ibuprofen: Potent COX Inhibitor for Inflammation Res

  2026-05-10

  (S)-(+)-Ibuprofen is a highly selective COX inhibitor used in inflammation pathway research. It offers superior potency and safety over the R-enantiomer, with well-defined pharmacokinetics. APExBIO’s B1018 product delivers reproducible results for pain mechanism studies and nonsteroidal anti-inflammatory drug research.

• 2-APB: Precision Control of ER-Ca2+-Calpain in Cell Fate Res

  2026-05-09

  This thought-leadership article explores how 2-APB (2-aminoethoxydiphenyl borate) empowers translational researchers to dissect and manipulate the ER-Ca2+-calpain axis, a central regulator of autophagy and apoptosis. Drawing on recent mechanistic insights from Bombyx mori starvation studies, it provides actionable guidance, protocol parameters, and a strategic vision for advancing oxidative stress and programmed cell death research. Distinct from standard product pages, this piece situates APExBIO’s 2-APB within a broader scientific and translational framework, highlighting its unique advantages and future potential.

453 records 18/31 page Previous Next First page 上5页 1617181920 下5页 Last page